Key Highlights

• Non-Negotiable Regulatory Step: Biocompatibility testing under ISO 10993 is a required prerequisite before FDA submission for devices like NASARIX.

• Covers Multiple Safety Categories: The standard evaluates cytotoxicity, sensitization, systemic toxicity, and genotoxicity, among other safety parameters.

• Relevant for a Broad Patient Base: Wide safety margins matter for a product intended for frequent nasal use by patients of varying ages and sensitivities.

Polyrizon's (NASDAQ: PLRZ) completion of ISO 10993 and FDA biocompatibility testing for its NASARIX Allergy Blocker nasal spray highlights a regulatory step that every medical device intended for human contact must satisfy before it can move toward market authorization.

ISO 10993 is a globally recognized series of standards used to evaluate whether materials in a medical device are safe for contact with the human body. It is not a single test but a framework covering multiple categories of biological risk assessment.

Among the core categories evaluated under ISO 10993 are cytotoxicity, which measures whether a material damages living cells, and systemic toxicity, which assesses whether exposure to the device could cause broader harmful effects beyond the immediate contact site. Sensitization and genotoxicity testing are also commonly required depending on the device's intended use and duration of contact.

For a product like NASARIX, which is designed for repeated nasal application, regulators place particular emphasis on long-term safety data rather than single-exposure risk. A device intended for chronic use needs to demonstrate that repeated contact does not introduce cumulative risk over time.

Polyrizon reported wide safety margins across the tested endpoints for NASARIX, a finding that carries added weight given the product's intended use case. Allergy prevention products are often used seasonally or year-round by patients across a wide age range, including children and older adults, populations that may have different physiological sensitivities.

Completing this stage of testing is generally treated as a prerequisite rather than a final milestone. It clears the way for a company to prepare formal submission materials for regulatory review, but it does not by itself constitute market clearance or approval.

The mucoadhesive design used in NASARIX is intended to form a physical barrier within the nasal passage that can block allergens before they trigger a reaction. Confirming that the barrier material itself is biologically safe is a necessary step before any claims about the product's allergy-blocking function can be evaluated in a regulatory submission.

Device developers across the medical technology sector routinely encounter ISO 10993 testing as one of the more time- and cost-intensive stages of pre-submission work, since it often requires multiple parallel studies conducted according to strict methodological standards.

For Polyrizon, passing this stage moves the company one step closer to formal regulatory engagement for NASARIX, though the company has not yet disclosed a specific timeline for submission or anticipated clearance.

Investors following early-stage medical device and consumer health companies often treat successful completion of biocompatibility testing as a meaningful, if intermediate, milestone on the path toward commercial launch.

 

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research and consult a licensed financial advisor before making any investment decisions. Past performance and regulatory or clinical milestones are not guarantees of future results.